Arterium Brings a New Product of Endocrinological Profile to Ukrainian Market

Arterium Corporation has expanded its range of anti-diabetic drugs. A new drug product, Mefarmil, is designed to be used in the therapy of type II diabetes mellitus.

Type II diabetes mellitus is a severe disease, which is spread all over the world, seriously hampers quality of life and leads to permanent disability and invalidism. The stable growth rate of the disease and diabetes mellitus incidence rate enhance the demand in anti-diabetic drugs. This unwelcome worldwide trend  motivated the Corporation to bring Mefarmil drug product to the pharmaceutical market of Ukraine.

Active ingredient of the drug is metformin. Metformin  used as mono- or combined therapy with insulin for treatment of adults and children over 10 years old  ;  are used to reduce the risk of complications in adult patients with type II diabetes and overweight with poor diet ,  ,particularly in patients suffering from obesity. Metformin reduces hyperglycemia with no risk to develop  hypoglycemia.

Mefarmil drug is available (product is represented) in three dosage forms  : 500 mg, 850 mg, and 1000 mg (that) ,which is  convenient () to select an individual dose for the patients.

The drug action is based upon the triple action principle () , specifically Mefarmil:

• reduces glucose generation in the liver;
• improves glucose uptake by muscle cells;
• slows down the glucose absorption in the intestine.

Definitely, (Undoubtedly,) Mefarmil does not affect one’s reaction speed while driving or operating other machinery, since the drug usage does not cause occurrence of hypoglycemia.

The drug product is available on prescription.

This information is intended solely for medical and pharmaceutical professionals to be used in their professional activity.

The information on the drug product is presented in concise form. You can find (the) (more) detailed information on the drug product in the instruction for use.

This website is a specialized information resource designed for medical and pharmaceutical professionals.